Abeona Therapeutics, Inc. (ABEO)

In the past six months, several events have influenced Abeona Therapeutics' stock price. The Centers for Medicare and Medicaid Services (CMS) established a permanent J-code for ZEVASKYN, effective January 2026, which is expected to streamline billing and access for providers. The first commercial patient treatment with ZEVASKYN was completed in December 2025, marking a significant commercial milestone. Abeona reported its Q4 and full-year 2025 financial results on March 17, 2026, reporting its first commercial revenue of $5.8 million for 2025, beating forecasts, the stock initially declined by 3.8% the day after the announcement. Since this earnings release, the stock has seen an upward trend, drifting approximately 25.0% higher. In April 2026, the activation of a new Qualified Treatment Center for ZEVASKYN in New York was announced, which positively impacted the stock, leading to a 5.24% gain on the day of the news. Insider sentiment has shown some negative signals due to open-market selling from key executives, although low-impact acquisitions have also occurred. The stock's 52-week trading range has been between $4.00 and $7.54.

There is no specific information available regarding demand seasonality for Abeona Therapeutics' products or services. Demand is likely driven by patient identification and treatment needs rather than seasonal fluctuations.

Abeona Therapeutics focuses on advancing innovative treatments for serious conditions. Its flagship product, ZEVASKYN, is an autologous cell-based gene therapy approved for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Beyond ZEVASKYN, Abeona's development pipeline includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical needs, such as ABO-503 for X-linked retinoschisis, ABO-504 for Stargardt disease, and ABO-505 for autosomal dominant optic atrophy. The company also utilizes its proprietary AIM vector platform programs to develop next-generation AAV-based gene therapies.

Abeona Therapeutics is headquartered in Cleveland, Ohio, where it also maintains a fully integrated cell and gene therapy cGMP manufacturing facility that serves as the production site for ZEVASKYN. The company's commercial reach for ZEVASKYN is expanding within the United States, with the activation of Qualified Treatment Centers (QTCs). NewYork-Presbyterian/Columbia University Irving Medical Center was established as a new QTC, broadening patient access across the New York metropolitan area and the Northeast.

Abeona Therapeutics' brand reputation has been significantly shaped by its progress in developing and commercializing gene therapies for rare diseases. The U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 was a major positive event, establishing it as the first and only autologous cell-based gene therapy for RDEB. The subsequent commercial launch and the ongoing expansion of Qualified Treatment Centers further contribute positively to its reputation by demonstrating the company's ability to bring approved therapies to patients. The company has faced past challenges, including a class-action lawsuit in 2016 and an investigation by Block & Leviton in April 2024. Despite this, the subsequent FDA approval of ZEVASKYN and its commercialization efforts indicate a recovery and positive trajectory for the company's standing in the biopharmaceutical industry.

Abeona Therapeutics' ownership is a mix of institutional, retail, and individual investors. Major institutional shareholders include Nantahala Capital Management, LLC, BlackRock, Inc., AIGH Capital Management LLC, and Vanguard Group Inc. Other notable institutional investors include Suvretta Capital Management, Llc, Cable Car Capital LLC, Vivo Capital, LLC, Geode Capital Management, Llc, Kennedy Capital Management, Inc., and Tang Capital Management Llc. Significant individual and insider owners include Sco Capital Partners LLC, holding 25.22% of the company's shares, and Steven H. Rouhandeh, with 24.50% ownership. Institutional investors collectively control approximately 44% of the company.